National Institutes of Health: Gastrointestinal Neoplasms trials

The registry lists 31 Gastrointestinal Neoplasms studies with National Institutes of Health as lead sponsor. 5 are open to participants now and 11 have results posted.

Early Phase 1 1Phase 1 11Phase 2 14Phase 3 1No phase 7(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor MicroenvironmentEnrolling by invitationNCT05600933
• Individual Response to Hyperthermic Intraperitoneal Chemotherapy (HIPEC) Treatment of Peritoneal Carcinomatosis From Peritoneal Mesothelioma or Atypical Mesothelial Proliferation or From Ovarian, Colorectal, or Appendiceal HistologiesRecruitingNCT04847063Phase 1
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 PatientsRecruitingNCT03190941Phase 1/2
• Acquisition of Blood and Tumor Tissue Samples From Patients With Gastrointestinal CancerRecruitingNCT01313442
• Harvesting Cells for Experimental Cancer TreatmentsEnrolling by invitationNCT00068003
• Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12D Variant of Mutated RAS in HLA-A*11:01 PatientsTerminatedNCT03745326Phase 1/2Results posted
• Messenger RNA (mRNA)-Based, Personalized Cancer Vaccine Against Neoantigens Expressed by the Autologous CancerTerminatedNCT03480152Phase 1/2Results posted
• Ability of a Dendritic Cell Vaccine to Immunize Melanoma or Epithelial Cancer Patients Against Defined Mutated Neoantigens Expressed by the Autologous CancerTerminatedNCT03300843Phase 2Results posted
• AZD9150, a STAT3 Antisense Oligonucleotide, in People With Malignant AscitesTerminatedNCT02417753Phase 2Results posted
• Mithramycin for Lung, Esophagus, and Other Chest CancersTerminatedNCT01624090Phase 2Results posted
• Temsirolimus and Bevacizumab in Treating Patients With Advanced Endometrial, Ovarian, Liver, Carcinoid, or Islet Cell CancerCompletedNCT01010126Phase 2Results posted
• Pazopanib Hydrochloride in Treating Patients With Advanced Neuroendocrine CancerCompletedNCT00454363Phase 2Results posted
• Bevacizumab and Erlotinib Hydrochloride in Treating Patients With Metastatic or Unresectable Biliary TumorsCompletedNCT00356889Phase 2Results posted
• Temsirolimus in Treating Patients With Metastatic Neuroendocrine CarcinomaCompletedNCT00093782Phase 2Results posted
• Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or GallbladderTerminatedNCT00085410Phase 2Results posted
• Debulking and Chemotherapy With or Without Intraperitoneal Chemotherapy to Treat Peritoneal CarcinomatosisCompletedNCT00052962Phase 3Results posted
• Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic CancerActive, not recruitingNCT06253520Phase 1
• Generation of Cancer Antigen-Specific T-cells From Human Induced Pluripotent Stem Cells (iPSC) for Research and Potential FutureTherapyTerminatedNCT03407040
• Alisertib and Combination Chemotherapy in Treating Patients With Gastrointestinal TumorsCompletedNCT02319018Phase 1
• Collecting Solid Tumor Tissue to Identify New TreatmentsCompletedNCT01658917
• Cixutumumab, Everolimus, and Octreotide Acetate in Treating Patients With Advanced Low to Intermediate Grade Neuroendocrine CarcinomaCompletedNCT01204476Phase 1
• Disease-Specific Questionnaire in Assessing Quality of Life in Patients With Gastrointestinal-Related Neuroendocrine TumorsStatus unknownNCT00454376
• Tumor Necrosis Factor in Patients Undergoing Surgery for Primary Cancer or Metastatic CancerCompletedNCT00436410Early Phase 1
• Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal CancerCompletedNCT00397384Phase 1
• EF5 and Motexafin Lutetium in Detecting Tumor Cells in Patients With Abdominal or Non-Small Cell Lung CancerTerminatedNCT00087191Not applicable
• Romidepsin in Treating Patients With Locally Advanced or Metastatic Neuroendocrine TumorsTerminatedNCT00084461Phase 2
• Gefitinib in Treating Patients With Progressive Metastatic Neuroendocrine TumorsCompletedNCT00075439Phase 2
• Bevacizumab and PEG-Interferon Alfa-2b in Treating Patients With Metastatic or Unresectable Carcinoid TumorsCompletedNCT00055809Phase 2
• 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007)CompletedNCT00031681Phase 1
• Interleukin-12 and Trastuzumab in Treating Patients With Cancer That Has High Levels of HER2/NeuCompletedNCT00004074Phase 1
• A Phase I Trial of Gemcitabine and Radiation in Locally Advanced Unresectable Cancer of the PancreasCompletedNCT00001431Phase 1